Zubin Bhagwagar

Zubin Bhagwagar

Auto-generated profile, based on publicly available information

Zubin Bhagwagar

Yale University

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2008 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
RSRajita Sinha
Rajita Sinha
HFHelen C Fox
Helen C Fox
KHKwangik A Hong
Kwangik A Hong
KBKeri Bergquist
Keri Bergquist
ZBZubin Bhagwagar
Zubin Bhagwagar
KSKristen M Siedlarz
Kristen M Siedlarz
Chronic alcohol abuse is associated with changes in stress and reward pathways that could alter vulnerability to emotional stress and alcohol craving. This study examines whether chronic alcohol abuse is associated with altered stress and alcohol craving responses. Treatment-engaged, 28-day abstinent alcohol-dependent individuals (ADs; 6F/22M), and social drinkers (SDs; 10F/18M) were exposed to a brief guided imagery of a personalized stressful, alcohol-related and neutral-relaxing situation, one imagery condition per session, presented in random order across 3 days. Alcohol craving, anxiety and emotion ratings, behavioral distress responses, heart rate, blood pressure, and salivary cortisol measures were assessed. Alcohol patients showed significantly elevated basal heart rate and salivary cortisol levels. Stress and alcohol cue exposure each produced a significantly enhanced and persistent craving state in alcohol patients that was marked by increased anxiety, negative emotion, systolic blood pressure responses, and, in the case of alcohol cue, behavioral distress responses, as compared to SDs. Blunted stress-induced cortisol responses were observed in the AD compared to the SD group. These data are the first to document that stress and cue exposure induce a persistent negative emotion-related alcohol craving state in abstinent alcoholics accompanied by dysregulated HPA and physiological arousal responses. As laboratory models of stress and negative mood-induced alcohol craving are predictive of relapse outcomes, one implication of the current data is that treatments targeting decreases in stress and alcohol cue-induced craving and regulation of stress responses could be of benefit in improving alcohol relapse outcomes.

1 June 2012 in Pain
Verified
Journal Article
Closed access
RDRobert H. Dworkin
Robert H. Dworkin
DTDennis C. Turk
Dennis C. Turk
SPSarah Peirce-Sandner
Sarah Peirce-Sandner
LBLaurie B. Burke
Laurie B. Burke
JFJohn T. Farrar
John T. Farrar
DZDan Ziegler
Dan Ziegler
A number of pharmacologic treatments examined in recent randomized clinical trials (RCTs) have failed to show statistically significant superiority to placebo in conditions in which their efficacy had previously been demonstrated. Assuming the validity of previous evidence of efficacy and the comparability of the patients and outcome measures in these studies, such results may be a consequence of limitations in the ability of these RCTs to demonstrate the benefits of efficacious analgesic treatments vs placebo ("assay sensitivity"). Efforts to improve the assay sensitivity of analgesic trials could reduce the rate of falsely negative trials of efficacious medications and improve the efficiency of analgesic drug development. Therefore, an Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials consensus meeting was convened in which the assay sensitivity of chronic pain trials was reviewed and discussed. On the basis of this meeting and subsequent discussions, the authors recommend consideration of a number of patient, study design, study site, and outcome measurement factors that have the potential to affect the assay sensitivity of RCTs of chronic pain treatments. Increased attention to and research on methodological aspects of clinical trials and their relationships with assay sensitivity have the potential to provide the foundation for an evidence-based approach to the design of analgesic clinical trials and expedite the identification of analgesic treatments with improved efficacy and safety.

1 June 2008 in CNS Spectrums
Verified
Journal Article
Closed access
PDF file
LMLeah McNally
Leah McNally
ZBZubin Bhagwagar
Zubin Bhagwagar
JHJonas Hannestad
Jonas Hannestad
Multiple lines of evidence suggest that inflammation and glutamate dysfunction contribute to the pathophysiology of depression. In this review we provide an overview of how these two systems may interact. Excess levels of inflammatory mediators occur in a subgroup of depressed patients. Studies of acute experimental activation of the immune system with endotoxin and of chronic activation during interferon-α treatment show that inflammation can cause depression. Peripheral inflammation leads to microglial activation which could interfere with excitatory amino acid metabolism leading to inappropriate glutamate receptor activation. Loss of astroglia, a feature of depression, upsets the balance of anti- and pro-inflammatory mediators and further impairs the removal of excitatory amino acids. Microglia activated by excess inflammation, astroglial loss, and inappropriate glutamate receptor activation ultimately disrupt the delicate balance of neuroprotective versus neurotoxic effects in the brain, potentially leading to depression.

1 July 2005 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
ZBZubin Bhagwagar
Zubin Bhagwagar
SHSepehr Hafizi
Sepehr Hafizi
PCPhilip J. Cowen
Philip J. Cowen

1 February 2004 in American Journal of Psychiatry
Verified
Journal Article
Closed access
ZBZubin Bhagwagar
Zubin Bhagwagar
MWMarzena Wylezinska
Marzena Wylezinska
MTMatthew Taylor
Matthew Taylor
PJPeter Jezzard
Peter Jezzard
PMPaul M. Matthews
Paul M. Matthews
PCPhilip J. Cowen
Philip J. Cowen

1 February 2011 in American Journal of Psychiatry
Verified
Journal Article
Closed access
KRKenneth Rando
Kenneth Rando
KHKwang-Ik Hong
Kwang-Ik Hong
ZBZubin Bhagwagar
Zubin Bhagwagar
CLChiang-Shan Ray Li
Chiang-Shan Ray Li
KBKeri Bergquist
Keri Bergquist
RSRajita Sinha
Rajita Sinha